A Case of a Gastrointestinal Stromal Tumor Diagnosed at the Postpartum Period

Abstract

Introduction. We discuss a rare gastrointestinal stromal tumor (GIST) case detected at the 10th postpartum week and we want to pay attention to the challenges and improvements in the diagnosis, surgery, chemotherapy, and follow-up of this rare tumor accompanied with the review of the current literature. Case Presentation. A 32-year-old multiparous woman presented with abdominal swelling 10 weeks after her second vaginal birth. Abdominal examination revealed a mass starting from the pelvic level and extending to the right upper quadrant. Radiological examinations showed a solid, multiloculated, and hypervascular mass starting from the pelvis and extending to the transverse colon. En bloc mass with a 20 cm jejunal segment resection and a left pelvic side wall peritonectomy with omentectomy was performed. The pathologic examination revealed a high-risk GIST which originated from the jejunum and disseminated to the peritoneum. The patient has been given imatinib 400 mg/day since then. She did not reveal any progression during the 15-month follow-up postoperatively. Conclusion. GIST tumors are rare and there is not sufficient information in the literature regarding its management. In this patient having high risk GIST and GIST sarcomatosis we successfully treated the patient by surgery and adjuvant imatinib chemotherapy.

ShRNA‐mediated BMI‐1 gene silencing inhibits gastrointestinal stromal tumor cell telomerase activity and enhances apoptosis

“…The clinical features of GISTs change due to the size and site of the tumor, and GISTs located in the gastrointestinal tract are more aggressive than those arising in the stomach [3]. For the treatment of GISTs, surgery and drugs achieve satisfactory therapeutic effects at the present stage [7], and the main treatments for GISTs are resection and anticancer and biological therapies, such as imatinib mesylate [8]. However, both extensive resections and limited local resections only have a small amount of experimental data, and traditional complete surgical resection with adjuvant therapy imminently improves survival in GISTs with a high risk of recurrence or metastasis [9,10].…”